Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | CHIEF BUSINESS OFFICER | January 02, 2025 | January 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2025 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 51,053 |
Ending reported balance
After 2025-01-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-01-02 · Grant · Acquired 8,750 · Balance 54,572 F1: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2: Each RSU represents a contingent right to receive one ordinary share. Row 2 · 2025-01-02 · Sale · Disposed 2,583 · Balance 51,989 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Row 3 · 2025-01-03 · Sale · Disposed 936 · Balance 51,053 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.75 inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-01-02 | Direct | 21,750 |
Reported balance
After 2025-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-01-02 · Grant · Acquired 21,750 · Balance 21,750 F6: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5).
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.75 inclusive.
F6: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 936 | $14.75 | $13,806.00 |
DisclosureSEC source: 0001415889-25-000925 · form4-01062025_070121.xml · nonDerivative · entry 3 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,053 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.75 inclusive. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 21,750 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000925 · form4-01062025_070121.xml · derivative · entry 4 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Ordinary Shares · 21,750 shares Expires 2035-01-02 F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 2,583 | $14.09 | $36,394.47 |
DisclosureSEC source: 0001415889-25-000925 · form4-01062025_070121.xml · nonDerivative · entry 2 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,989 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000925 · form4-01062025_070121.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,572 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:50 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 972 | $22.26 | $21,636.72 |
DisclosureSEC source: 0001415889-24-024768 · form4-10042024_041004.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,822 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 22:55 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 967 | $19.64 | $18,991.88 |
DisclosureSEC source: 0001415889-24-019386 · form4-07082024_060707.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,794 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 955 | $23.81 | $22,738.55 |
DisclosureSEC source: 0001415889-24-010415 · form4-04052024_040432.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,761 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 23:28 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 2,643 | $17.50 | $46,252.50 |
DisclosureSEC source: 0001209191-24-000879 · doc4.xml · nonDerivative · entry 2 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,716 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:28 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $18.08 | $0.00 |
DisclosureSEC source: 0001209191-24-000879 · doc4.xml · derivative · entry 3 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Ordinary Shares · 44,000 shares Expires 2034-01-02 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:28 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000879 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,359 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 21:48 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 442 | $20.00 | $8,840.00 |
DisclosureSEC source: 0001209191-23-052252 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,359 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:49 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 451 | $25.10 | $11,320.10 |
DisclosureSEC source: 0001209191-23-041569 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,801 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:40 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 447 | $21.11 | $9,436.17 |
DisclosureSEC source: 0001209191-23-023344 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,252 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-23-002211 · doc4.xml · derivative · entry 3 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2033-01-03 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,801 | $29.06 | $52,337.06 |
DisclosureSEC source: 0001209191-23-002211 · doc4.xml · nonDerivative · entry 2 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,699 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002211 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:17 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $60.87 | $0.00 |
DisclosureSEC source: 0001209191-22-001806 · doc4.xml · derivative · entry 2 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2023 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:17 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001806 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2023 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,019 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 15 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,764 Underlying: Ordinary Shares · 13,019 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on February 21, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,256 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 14 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,750 Underlying: Ordinary Shares · 19,256 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 40,426 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 13 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,660 Underlying: Ordinary Shares · 40,426 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,121 | $33.09 | $103,273.89 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 9 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50 inclusive. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 69,580 | $32.41 | $2,255,087.80 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 8 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,121 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.99 inclusive. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 13,019 | $15.36 | $199,971.84 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 7 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 19,256 | $9.82 | $189,093.92 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 6 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 40,426 | $11.66 | $471,367.16 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 5 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 974 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 12 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,783 Underlying: Ordinary Shares · 974 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on February 21, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,723 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 11 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,006 Underlying: Ordinary Shares · 1,723 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,331 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 10 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,086 Underlying: Ordinary Shares · 4,331 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 7,028 | $32.03 | $225,106.84 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 4 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 974 | $15.36 | $14,960.64 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 3 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 1,723 | $9.82 | $16,919.86 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 2 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 22:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 4,331 | $11.66 | $50,499.46 |
DisclosureSEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:22 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 271 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-21-046009 · doc4.xml · derivative · entry 3 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,729 Underlying: Ordinary Shares · 271 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:22 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 271 | $32.00 | $8,672.00 |
DisclosureSEC source: 0001209191-21-046009 · doc4.xml · nonDerivative · entry 2 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:22 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 271 | $9.82 | $2,661.22 |
DisclosureSEC source: 0001209191-21-046009 · doc4.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:28 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 70,500 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001209191-21-001335 · doc4.xml · derivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,500 Underlying: Common Stock · 70,500 shares Expires 2031-01-04 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 4, 2022 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:42 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 44,757 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0001209191-20-012510 · doc4.xml · derivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,757 Underlying: Common Stock · 44,757 shares Expires 2030-02-21 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on February 21, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:55 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-001925 · doc4.xml · derivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 20:37 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (Right to Buy) · Derivative | 152,174 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-19-051100 · doc4.xml · derivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,174 Underlying: Ordinary Shares · 152,174 shares Expires 2029-09-26 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments. Read SEC document |
| September 26, 2019 Filed Jan 6, 2020 21:50 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (Right to Buy) · Derivative | 107,417 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-20-001912 · doc4a.xml · derivative · entry 1 Crockett Nigel · CIK 0001788580 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,417 Underlying: Ordinary Shares · 107,417 shares Expires 2029-09-26 F1 · shares: The number of options granted on September 26, 2019 was incorrectly listed as 152,174 on the original Form 4. This amendment is being filed to correct the inadvertent error. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments. F1 · derivative.underlying_shares: The number of options granted on September 26, 2019 was incorrectly listed as 152,174 on the original Form 4. This amendment is being filed to correct the inadvertent error. F1 · balance_after: The number of options granted on September 26, 2019 was incorrectly listed as 152,174 on the original Form 4. This amendment is being filed to correct the inadvertent error. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.